Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Relmada Therapeutics ( (RLMD) ) has shared an announcement.
On September 17, 2025, Relmada Therapeutics updated its corporate presentation, highlighting the progress of its drug candidates. The company is advancing its NDV-01 treatment for NMIBC, which has shown positive Phase 2a data, and plans to initiate further studies in 2026. This development positions Relmada to address significant unmet needs in NMIBC treatment, potentially impacting patient care and the company’s market position.
The most recent analyst rating on (RLMD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Relmada Therapeutics stock, see the RLMD Stock Forecast page.
Spark’s Take on RLMD Stock
According to Spark, TipRanks’ AI Analyst, RLMD is a Neutral.
Relmada Therapeutics’ overall score reflects its high-risk, high-reward profile typical of biotechnology firms in developmental stages. The company’s financial performance is weakened by zero revenue and significant cash burn, tempered by strong cash reserves. Strategic pipeline developments and recent acquisitions offer potential upside, but are countered by challenges such as discontinued projects and reliance on external financing. Technical analysis shows short-term momentum, but the overall outlook remains speculative.
To see Spark’s full report on RLMD stock, click here.
More about Relmada Therapeutics
Relmada Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing therapies for central nervous system disorders. The company is engaged in creating innovative treatments, including a pipeline of potential high-value assets targeting conditions like non-muscle invasive bladder cancer (NMIBC) and Prader-Willi Syndrome.
Average Trading Volume: 707,050
Technical Sentiment Signal: Sell
Current Market Cap: $55.43M
For an in-depth examination of RLMD stock, go to TipRanks’ Overview page.